New data from teva shows substantial rates of undertreated tardive dyskinesia in long-term care settings at psych congress elevate 2025

Parsippany, n.j. and tel aviv, israel, may 30, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced results from a study of treatment patterns among patients with tardive dyskinesia (td) residing in long-term care (ltc) facilities, highlighting a critical gap in td diagnosis and treatment.
TEVA Ratings Summary
TEVA Quant Ranking